AKRO · Akero Therapeutics
Acquired Company
Novo Nordisk completed acquisition of Akero Therapeutics on 12/9/2025 for US $54 per share in cash and a non-transferable Contingent Value Right (CVR), representing a total transaction value of about US $4.7 billion.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, is dedicated to developing medications designed to restore metabolic balance and improve overall health. The company is headquartered in South San Francisco, California.
601 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, South San Francisco, CA, 94080, USA
BIOTECHNOLOGY
HEALTHCARE
Market Cap
4.499B
52 Wk Range
$31.80 - $57.35
Previous Close
$54.65
Open
$54.65
Volume
N/A
Day Range
$54.65 - $54.65
Enterprise Value
3.762B
Cash
176M
Avg Qtr Burn
-67.17M
Insider Ownership
1.46%
Institutional Own.
N/A
Qtr Updated
Sep 30th 2025